Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of MK-6070 plus durvalumab versus durvalumab alone as consolidation therapy in limited-stage small cell lung cancer
MOH_2026-08-25_017006Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of gocatamig and durvalumab in small cell lung cancer (SCLC), sponsored by Merck & Co. Started Aug 2026; status: recruiting.
02
Drugs
gocatamigdurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on MOH_2026-08-25_017006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-08-25_017006.